Literature DB >> 12443667

Ratios of subclinical to clinical Japanese encephalitis (JE) virus infections in vaccinated populations: evaluation of an inactivated JE vaccine by comparing the ratios with those in unvaccinated populations.

Eiji Konishi1, Tomoyuki Suzuki.   

Abstract

Japanese encephalitis (JE) virus is characterized as a virus that produces a large number of subclinical infections. In this report, we estimated a ratio of subclinical to clinical infections in vaccinated human populations who acquired natural infection with JE virus, and evaluated protective capacity of the currently approved inactivated JE vaccine by comparing the ratio with those reported for unvaccinated populations. We developed a sensitive immunostaining method for detecting nonstructural 1 (NS1) antibody to demonstrate JE virus infection in vaccinated individuals. Serum samples collected from human populations in western Japan showed NS1 antibody prevalences of approximately 10% in an urban area in 1981 and 1995 and 20% in a rural area from 1982 through 1983. Analysis of annual change in NS1 antibody titer using paired samples provided a mean duration of NS1 antibody responses of approximately 2 years, indicating that 5% of the urban population or 10% of the rural population acquired natural JE virus infection in 1 year. Based on the number of JE cases from 1982 through 1991 and the number of people acquiring natural infection, and on the assumption that annual infection rates obtained in the present study areas are representative of the infection rate in entire Japan except for non-endemic northern areas, the ratio of subclinical to clinical infections in vaccinated populations was estimated to be 2000000:1, which was 2000-80000 times higher than the ratio previously reported for unvaccinated populations.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12443667     DOI: 10.1016/s0264-410x(02)00433-4

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  16 in total

1.  Development and evaluation of an enzyme-linked immunosorbent assay for quantifying antibodies to Japanese encephalitis virus nonstructural 1 protein to detect subclinical infections in vaccinated horses.

Authors:  Eiji Konishi; Mizue Shoda; Naoko Ajiro; Takashi Kondo
Journal:  J Clin Microbiol       Date:  2004-11       Impact factor: 5.948

2.  Nonstructural protein 1-specific immunoglobulin M and G antibody capture enzyme-linked immunosorbent assays in diagnosis of flaviviral infections in humans.

Authors:  Day-Yu Chao; Jedhan Ucat Galula; Wen-Fan Shen; Brent S Davis; Gwong-Jen J Chang
Journal:  J Clin Microbiol       Date:  2014-12-10       Impact factor: 5.948

3.  JE-ADVAX vaccine protection against Japanese encephalitis virus mediated by memory B cells in the absence of CD8(+) T cells and pre-exposure neutralizing antibody.

Authors:  Maximilian Larena; Natalie A Prow; Roy A Hall; Nikolai Petrovsky; Mario Lobigs
Journal:  J Virol       Date:  2013-02-06       Impact factor: 5.103

4.  A mouse monoclonal antibody against dengue virus type 1 Mochizuki strain targeting envelope protein domain II and displaying strongly neutralizing but not enhancing activity.

Authors:  Atsushi Yamanaka; Tomohiro Kotaki; Eiji Konishi
Journal:  J Virol       Date:  2013-09-18       Impact factor: 5.103

5.  Establishment of an Algorithm Using prM/E- and NS1-Specific IgM Antibody-Capture Enzyme-Linked Immunosorbent Assays in Diagnosis of Japanese Encephalitis Virus and West Nile Virus Infections in Humans.

Authors:  Jedhan U Galula; Gwong-Jen J Chang; Shih-Te Chuang; Day-Yu Chao
Journal:  J Clin Microbiol       Date:  2015-12-09       Impact factor: 5.948

6.  An inactivated Vero cell-grown Japanese encephalitis vaccine formulated with Advax, a novel inulin-based adjuvant, induces protective neutralizing antibody against homologous and heterologous flaviviruses.

Authors:  Mario Lobigs; Megan Pavy; Roy A Hall; Päivi Lobigs; Peter Cooper; Tomoyoshi Komiya; Hiroko Toriniwa; Nikolai Petrovsky
Journal:  J Gen Virol       Date:  2010-02-03       Impact factor: 3.891

7.  Seroprevalence of Japanese encephalitis virus infection in captive Japanese macaques (Macaca fuscata).

Authors:  Hiroshi Shimoda; Akatsuki Saito; Keita Noguchi; Yutaka Terada; Ryusei Kuwata; Hirofumi Akari; Tomohiko Takasaki; Ken Maeda
Journal:  Primates       Date:  2014-04-19       Impact factor: 2.163

8.  Epitope-blocking enzyme-linked immunosorbent assay to differentiate west nile virus from Japanese encephalitis virus infections in equine sera.

Authors:  Yoko Kitai; Mizue Shoda; Takashi Kondo; Eiji Konishi
Journal:  Clin Vaccine Immunol       Date:  2007-06-27

9.  Utilization of complement-dependent cytotoxicity to measure low levels of antibodies: application to nonstructural protein 1 in a model of Japanese encephalitis virus.

Authors:  Eiji Konishi; Yoko Kitai; Takashi Kondo
Journal:  Clin Vaccine Immunol       Date:  2007-11-21

10.  Live chimeric and inactivated Japanese encephalitis virus vaccines differ in their cross-protective values against Murray Valley encephalitis virus.

Authors:  Mario Lobigs; Maximilian Larena; Mohammed Alsharifi; Eva Lee; Megan Pavy
Journal:  J Virol       Date:  2008-12-24       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.